Shh-Gli2-Runx2 inhibits vascular calcification

Aoran Huang1, Tianhua Xu1, Xiaomei Lu2

  • 1Department of Nephrology, The First Hospital of China Medical University, Shenyang, China.

Insights

Shh signaling, a key pathway in bone formation, was found to be decreased in vascular calcification (VC). Restoring Shh levels inhibited VC, suggesting Shh as a potential therapeutic target for this condition.

Area of Science:

  • Cardiovascular Biology
  • Renal Medicine
  • Molecular Biology

Background:

  • Vascular calcification (VC) is a common complication in chronic kidney disease (CKD) and significantly increases mortality risk.
  • Shh, a ligand in Hedgehog (Hh) signaling, is involved in osteogenesis and cardiovascular diseases, but its role in VC remains unexplored.

Purpose of the Study:

  • To investigate the role of Shh signaling in the development of vascular calcification (VC) in chronic kidney disease (CKD).
  • To explore Shh as a potential therapeutic target for treating VC.

Main Methods:

  • Vascular smooth muscle cells (VSMCs) were induced to calcify using inorganic phosphorus.
  • Vascular calcification (VC) was induced in mice using an adenine diet supplemented with phosphorus.
  • Shh signaling pathway modulation was achieved using agonists (SAG) and antagonists (CPN), and gene manipulation (overexpression/silencing) of Shh and Gli2.

Main Results:

  • Shh levels were reduced in calcified VSMCs, arteries of mice with VC, and radial arteries of CKD patients with VC.
  • Shh overexpression inhibited VSMC calcification, while Shh silencing accelerated it.
  • Hedgehog signaling agonist (SAG) alleviated VC, whereas antagonist (CPN) worsened it.
  • Shh inhibited VC via Gli2, which promoted Runx2 degradation, independent of Smurf1 and Cullin4B.

Conclusions:

  • Shh signaling plays a protective role against vascular calcification (VC).
  • The study elucidates the mechanism of Shh in preventing VC through Gli2-mediated Runx2 degradation.
  • Shh emerges as a promising therapeutic target for managing vascular calcification in CKD.
Abstract

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.6K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K